Hepatitis C Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Hepatitis C occurs with multiple symptoms including abdominal pain, fatigue, fever, jaundice, loss of appetite, nausea, and vomiting. The predisposing factors of hepatitis C include dialysis, organ transplant, and blood transfusion.

The Hepatitis C pipeline drugs market research report provides an analysis of the Hepatitis C drugs by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The guide also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hepatitis C and features dormant and discontinued projects.

Key Targets of the Hepatitis C Pipeline Drugs Market

Some of the targets of the Hepatitis C pipeline drugs market are Nonstructural Protein 5A, NS5B, Hepacivirin, Hepatitis C Virus Envelope Protein E2, Interferon Alpha/Beta Receptor 1, Interferon Alpha/Beta Receptor 2, Hepatitis C Virus Envelope Protein E1, Nonstructural Protein 3, Cytochrome P450 3A4, Hepatitis C Virus P7 Protein, microRNA 122, Nonstructural Protein 4B and DNA (Apurinic or Apyrimidinic Site) Lyase among others.

Hepatitis C Pipeline Drugs Market, by Key Targets

For more insights on key targets, download a free report sample

Key Mechanisms of Action in the Hepatitis C Pipeline Drugs Market

The key mechanisms of action of the Hepatitis C pipeline drugs market are Nonstructural Protein 5A Inhibitor, NS5B Inhibitor, Hepacivirin Inhibitor, Hepatitis C Virus Envelope Protein E2 Inhibitor, Interferon Alpha/Beta Receptor 1 Agonist, Interferon Alpha/Beta Receptor 2 Agonist, Hepatitis C Virus Envelope Protein E1 Inhibitor, Nonstructural Protein 3 Inhibitor, Cytochrome P450 3A4 Inhibitor, Hepatitis C Virus P7 Protein Inhibitor, microRNA 122 Inhibitor, Nonstructural Protein 4B Inhibitor and DNA (Apurinic or Apyrimidinic Site) Lyase Inhibitor among others.

Hepatitis C Pipeline Drugs Market, by Mechanisms of Action

For more insights on mechanisms of action, download a free report sample

Key Routes of Administration in the Hepatitis C Pipeline Drugs Market

The routes of administration in the Hepatitis C pipeline drugs market are oral, subcutaneous, intravenous, intradermal, intramuscular, intravenous drip, intralesional, intraperitoneal, and intrathecal.

Hepatitis C Pipeline Drugs Market, by Routes of Administration

For more insights on routes of administration, download a free report sample

Key Molecule Types in the Hepatitis C Pipeline Drugs Market

The molecule types in the Hepatitis C pipeline drugs market are Small Molecule, Subunit Vaccine, Monoclonal Antibody, Recombinant Protein, DNA Vaccine, Fusion Protein, Peptide, Recombinant Vector Vaccine, Synthetic Peptide, Vaccine, Antisense RNAi Oligonucleotide, RNAi Gene Therapy, Gene Therapy, Inactivated Vaccine and Protein.

Hepatitis C Pipeline Drugs Market, by Molecule Types

For more insights on molecule type, download a free report sample

Key Companies in the Hepatitis C Pipeline Drugs Market

Some of the key companies in the Hepatitis C pipeline drugs market are Merck & Co Inc, AbbVie Inc, Cocrystal Pharma Inc, Gilead Sciences Inc, AB Pharma Ltd, HEC Pharma Co Ltd, Atea Pharmaceuticals Inc, Biotron Ltd, and F. Hoffmann-La Roche Ltd among others.

Hepatitis C Pipeline Drugs Market, by Key Companies

For more insights on key companies, download a free report sample

Hepatitis C Pipeline Drugs Market Report Overview

Scope 

• The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis C (Infectious Disease).
• The pipeline guide reviews pipeline therapeutics for Hepatitis C (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Hepatitis C (Infectious Disease) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Hepatitis C (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis C (Infectious Disease)

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Hepatitis C (Infectious Disease).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Hepatitis C (Infectious Disease) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.